Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Oronsky

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Translational Oncology|April 27, 2018
A Review of Clinical Radioprotection and Chemoprotection for Oral MucositisBryan Oronsky, Sharad Goyal, Michelle M Kim, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Medical Oncology (Northwood, London, England)|July 6, 2016
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generationMarcel H Fens, Pedro Cabrales, Jan Scicinski, et al.
Case Reports in Oncology|May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic SyndromeChristina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Case Reports in Oncology|April 12, 2016
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum DoubletsCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Translational Oncology|April 27, 2018
A Review of Clinical Radioprotection and Chemoprotection for Oral MucositisBryan Oronsky, Sharad Goyal, Michelle M Kim, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Medical Oncology (Northwood, London, England)|July 6, 2016
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generationMarcel H Fens, Pedro Cabrales, Jan Scicinski, et al.
Case Reports in Oncology|May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic SyndromeChristina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Case Reports in Oncology|April 12, 2016
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum DoubletsCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Pageof 3